Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. Wallace DJ, et al. Among authors: chatham ww. Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699. Arthritis Rheum. 2009. PMID: 19714604 Free PMC article. Clinical Trial.
Novel evidence-based systemic lupus erythematosus responder index.
Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Furie RA, et al. Among authors: chatham ww. Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698. Arthritis Rheum. 2009. PMID: 19714615 Free PMC article.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group. Furie R, et al. Among authors: chatham ww. Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. Arthritis Rheum. 2011. PMID: 22127708 Free PMC article. Clinical Trial.
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group. Stohl W, et al. Among authors: chatham ww. Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400. Arthritis Rheum. 2012. PMID: 22275291 Free PMC article. Clinical Trial.
Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.
Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group. Chatham WW, et al. J Rheumatol. 2012 Aug;39(8):1632-40. doi: 10.3899/jrheum.111587. Epub 2012 Jun 15. J Rheumatol. 2012. PMID: 22707609 Free article. Clinical Trial.
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, Chitkara P, Putterman C, Gross RL, Somers EC, Kirou KA, Ramsey-Goldman R, Hsieh C, Buyon JP, Dervieux T, Weinstein A. Kalunian KC, et al. Among authors: chatham ww. Arthritis Rheum. 2012 Dec;64(12):4040-7. doi: 10.1002/art.34669. Arthritis Rheum. 2012. PMID: 22932861 Free article.
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group. Ginzler EM, et al. Among authors: chatham ww. J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1. J Rheumatol. 2014. PMID: 24187095 Free article. Clinical Trial.
Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.
Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T. Putterman C, et al. Among authors: chatham ww. Lupus Sci Med. 2014 Oct 1;1(1):e000056. doi: 10.1136/lupus-2014-000056. eCollection 2014. Lupus Sci Med. 2014. PMID: 25396070 Free PMC article.
Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.
Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. Aranow C, et al. Among authors: chatham ww. Arthritis Rheumatol. 2015 Jul;67(7):1848-57. doi: 10.1002/art.39108. Arthritis Rheumatol. 2015. PMID: 25777546 Free PMC article. Clinical Trial.
76 results